Abstract：Objective To investigate the application effect of two-stage citric acid anticoagulant therapy in hemodialysis patients with active bleeding or high risk of bleeding. Methods A total of 100 hemodialysis patients with active bleeding or high risk of bleeding admitted to Liuzhou Worker’s Hospital, Guangxi Zhuang Autonomous Region from May 2021 to March 2022 were selected as the study objects, and they were divided into study group and control group according to random number table method, with 50 cases in each group. The control group was treated with one-stage citric acid anticoagulant therapy, while the study group was treated with two-stage citric acid anticoagulant therapy. The dialysis time, anticoagulant efficiency of dialyzer, anticoagulant efficiency of intravenous pot of the two groups were compared, and the hemodialysis blood gas index, peripheral blood serum electrolyte level, and urea clearance at the end of dialysis were compared between the two groups. The occurrence of adverse events in both groups was recorded. Results The dialysis time of the study group was longer than that of the control group, and the anticoagulant effect of intravenous pot was higher than that of the control group, the differences were statistically significant (P＜0.05). After dialysis, the blood pH value and HCO3- of the two groups were higher than those before treatment, and the differences were statistically significant (P＜0.05). The online Kt/V value of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05). During dialysis, there was no significant difference in the total incidence of adverse events between the two groups (P＞0.05). Conclusion For hemodialysis patients with active bleeding or high risk of bleeding, two-stage citric acid anticoagulant therapy is superior to one-stage citric acid anticoagulant therapy in terms of dialysis time, anticoagulant efficiency of intravenous pot, and urea clearance in hemodialysis.
吴春香 刘春晓 张崔勇 罗舒文 韦新月 罗春明. 两段式柠檬酸抗凝治疗在活动性出血或高危出血风险的血液透析患者中的应用效果[J]. 中国医药导报, 2023, 20(34): 120-123.
WU Chunxiang LIU Chunxiao ZHANG Cuiyong LUO Shuwen WEI Xinyue LUO Chunming. Application effect of two-stage citric acid anticoagulant therapy in hem-odialysis patients with active bleeding or high risk of bleeding. 中国医药导报, 2023, 20(34): 120-123.
[1] World Health Organization. Wodd Health Statistics 2020 [R]. Geneva：World Health Organization，2020. [2] 白雪莲，张佳宜，项国梁，等.中国成人慢性肾脏病患病率的meta分析[J].中国医药科学，2022，12（9）：49-53. [3] Fresenius K. Medical care-healthcare professionals [EB/OL].（2020-01-01）[2022-08-28].https：www.freseniusmedicalcare.cn/. [4] 陈香美.血液净化标准操作规程[M].北京：人民军医出版社，2021：107. [5] Morita Y，Johnson RW，Dorn RE，et al. Regional anticoagulation during hemodialysis using citrate [J]. Am J Med Sci，1961，242：32-43. [6] Buturovic-Ponikvar J，Cerne S，Gubensek J，et al. Regional citcrate anticoagulation for hemodialysis：calcium-free vs.calcium containing dialysate-a randomized trial [J]. Int J Artif Organs，2008，31（5）：418-424. [7] 张东亮，张潘，张周沧.分段枸橼酸抗凝进行含钙透析液高通量血液透析的临床观察[J].中国血液净化，2016，15（12）：686-690. [8] 朱淑华，樊蓉，徐斌，等.简化枸橼酸抗凝无肝素透析的疗效观察[J].肾脏病与透析肾移植杂志，2017，26（4）：323-327. [9] 许敏敏，彭婷，俞跃，等.分段式枸橼酸抗凝在高危出血风险血液透析患者中的临床应用[J].中国现代医药杂志，2021，23（9）：25-30. [10] Wright S， Steinwandel U， Ferrari P，et al. Citrate anticoagulation using ACD solution A during long-term haemodialy [J]. Nephrology，2011，16（4）：396-402. [11] Wang X，Tirucherai G，Marbury TC，et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis [J]. J Clin Pharmacol，2016，56（5）：628-636. [12] Kaw D，Malhotra D. Platelet dysfunction and end-stage renal disease [J]. Semin Dial，2006，19（4）：317-322. [13] Gangji AS，Sohal AS，Treleaven D，et al. Bleeding in patients with renal insufficiency：a practical guide to clinical management [J]. Thromb Res，2006，118（3）：423-428. [14] Evenepoel P，Maes B，Vanwalleghem J，et al. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate [J]. Am J Kidney Dis，2002， 39（2）：315-323. [15] 黄艳玲，陈永华，袁利，等.高危出血倾向患者血液透析中局部枸橼酸抗凝的应用[J].临床和实验医学杂志，2019，18（18）：2002-2005. [16] 张少岩，李月红，杨画，等.简化枸橼酸抗凝血液透析治疗方案在高出血风险患者血液透析中的应用[J].临床内科杂志，2021，38（1）：34-36. [17] Mahmood D，Stegmayr BG. Haemodialysis with Tinzaparin versus dialysate citrate as anticoagulation [J]. Blood Purif，2018，46（3）：257-263. [18] Buturovic-Ponikvar J，Gubensek J，Ponikvar R. Citrate anticoagulation for postdilutional online hemodiafiltration with calcium-containing dialysate and infusate：significant clotting in the venous bubble trap [J]. Int J Artif Organs，2008， 31（4）：323-328. [19] 席春生，刘同存，刘飞，等.低剂量两段法枸橼酸抗凝血液透析的临床疗效观察[J].中国现代医学杂志，2020， 30（16）：63-66. [20] 廖晨旭.两段式枸橼酸钠抗凝法在高危出血患者血液透析中的应用效果研究[J].当代医药论丛.2022，20（4）：90-93. [21] Tang X，Chen D，Zhang L，et al. Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis：a prospective multicenter randomized controlled trial [J]. J Zhejiang Univ Sci B，2022， 23（11）：931-942. [22] 陈娟娟，孙岩，何丽莉，等.不同浓度枸橼酸钠分段式抗凝方案在血液透析患者中的抗凝效果对比[J].临床输血与检验，2022，24（4）：469-475. [23] Flythe JE，Curhan GC，Brunelli SM. Disentangling the ultrafiltration ratemortality association：the respective roles of session length and weight gain [J].Clin J Am Soc Nephrol，2013，8（7）：1151-1161. [24] Kovaci■ V. Kt/V as a measure of hemodialysis adequacy [J]. Lijec Vjesn，2003，125（7/8）：188-191. [25] Bicakci Z，Olcay L. Citrate metabolism and its complications in non-massive blood transfusions：association with decompensated metabolic alkalosis respiratory acidosis and serum electrolyte levels [J]. Transfus Apher Sci，2014，50（3）：418-426.
2023, Vol. 20 
京公网安备 11010502046598号